DexCom, Inc. (DXCM)
DXCM Stock Price Chart
Explore DexCom, Inc. interactive price chart. Choose custom timeframes to analyze DXCM price movements and trends.
DXCM Company Profile
Discover essential business fundamentals and corporate details for DexCom, Inc. (DXCM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
14 Apr 2005
Employees
10.20k
Website
https://www.dexcom.comCEO
Jacob Steven Leach
Description
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DXCM Financial Timeline
Browse a chronological timeline of DexCom, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.61, while revenue estimate is $1.29bn.
Earnings released on 30 Apr 2026
EPS came in at $0.56 surpassing the estimated $0.47 by +20.27%, while revenue for the quarter reached $1.19bn , beating expectations by +1.47%.
Earnings released on 12 Feb 2026
EPS came in at $0.68 surpassing the estimated $0.65 by +4.62%, while revenue for the quarter reached $1.26bn , beating expectations by +0.91%.
Earnings released on 30 Oct 2025
EPS came in at $0.61 surpassing the estimated $0.58 by +5.90%, while revenue for the quarter reached $1.21bn , beating expectations by +2.16%.
Earnings released on 30 Jul 2025
EPS came in at $0.48 surpassing the estimated $0.44 by +8.21%, while revenue for the quarter reached $1.16bn , beating expectations by +2.89%.
Earnings released on 1 May 2025
EPS came in at $0.32 falling short of the estimated $0.33 by -2.20%, while revenue for the quarter reached $1.04bn , beating expectations by +1.83%.
Earnings released on 13 Feb 2025
EPS came in at $0.45 falling short of the estimated $0.48 by -6.09%, while revenue for the quarter reached $1.11bn , beating expectations by +0.39%.
Earnings released on 24 Oct 2024
EPS came in at $0.45 surpassing the estimated $0.44 by +2.27%, while revenue for the quarter reached $994.20m , beating expectations by +0.38%.
Earnings released on 25 Jul 2024
EPS came in at $0.43 surpassing the estimated $0.39 by +10.26%, while revenue for the quarter reached $1.00bn , missing expectations by -3.17%.
Earnings released on 25 Apr 2024
EPS came in at $0.32 surpassing the estimated $0.27 by +18.52%, while revenue for the quarter reached $921.00m , beating expectations by +1.22%.
Earnings released on 8 Feb 2024
EPS came in at $0.50 surpassing the estimated $0.43 by +16.28%, while revenue for the quarter reached $1.03bn , beating expectations by +2.01%.
Earnings released on 26 Oct 2023
EPS came in at $0.50 surpassing the estimated $0.34 by +47.06%, while revenue for the quarter reached $975.00m , beating expectations by +3.81%.
Earnings released on 27 Jul 2023
EPS came in at $0.34 surpassing the estimated $0.23 by +47.83%, while revenue for the quarter reached $871.30m , beating expectations by +3.53%.
Earnings released on 27 Apr 2023
EPS came in at $0.17 surpassing the estimated $0.15 by +13.33%, while revenue for the quarter reached $741.50m , beating expectations by +2.88%.
Earnings released on 9 Feb 2023
EPS came in at $0.34 surpassing the estimated $0.26 by +30.77%, while revenue for the quarter reached $815.20m , beating expectations by +0.63%.
Earnings released on 27 Oct 2022
EPS came in at $0.28 surpassing the estimated $0.24 by +16.67%, while revenue for the quarter reached $769.60m , beating expectations by +2.37%.
Earnings released on 28 Jul 2022
EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $696.20m , missing expectations by -0.19%.
Stock split effective on 13 Jun 2022
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Apr 2022
EPS came in at $0.08 falling short of the estimated $0.13 by -38.46%, while revenue for the quarter reached $628.80m , beating expectations by +0.79%.
Earnings released on 10 Feb 2022
EPS came in at $0.17 falling short of the estimated $0.22 by -22.73%, while revenue for the quarter reached $698.20m , beating expectations by +0.10%.
Earnings released on 28 Oct 2021
EPS came in at $0.22 surpassing the estimated $0.16 by +37.50%, while revenue for the quarter reached $650.20m , beating expectations by +5.26%.
Earnings released on 29 Jul 2021
EPS came in at $0.19 surpassing the estimated $0.11 by +72.73%, while revenue for the quarter reached $595.10m , beating expectations by +15.82%.
DXCM Stock Performance
Access detailed DXCM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
